TD Cowen Cuts Humana (NYSE:HUM) Price Target to $173.00

Humana (NYSE:HUM) had its price objective trimmed by TD Cowen from $260.00 to $173.00 in a report published on Friday morning, Marketbeat reports. The firm currently has a hold rating on the insurance provider’s stock.

Other equities analysts also recently issued reports about the stock. Zacks Research downgraded shares of Humana from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. UBS Group lowered their price target on shares of Humana from $285.00 to $195.00 and set a “neutral” rating on the stock in a research report on Thursday. Barclays restated an “underperformer” rating on shares of Humana in a research report on Monday, January 5th. Evercore ISI reduced their target price on Humana from $260.00 to $180.00 in a research note on Thursday. Finally, Wells Fargo & Company cut Humana from an “overweight” rating to a “cautious” rating in a report on Wednesday, January 7th. Seven investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus price target of $238.29.

Humana Stock Performance

Shares of HUM stock opened at $183.92 on Friday. The stock has a fifty day moving average price of $244.65 and a 200 day moving average price of $261.02. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.00. The stock has a market cap of $22.12 billion, a PE ratio of 18.73, a P/E/G ratio of 1.96 and a beta of 0.44. Humana has a 1 year low of $169.61 and a 1 year high of $315.35.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $0.05. The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.Humana’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Sell-side analysts forecast that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HUM. Transamerica Financial Advisors LLC grew its position in shares of Humana by 36.1% in the fourth quarter. Transamerica Financial Advisors LLC now owns 490 shares of the insurance provider’s stock valued at $126,000 after purchasing an additional 130 shares during the period. UMB Bank n.a. lifted its position in Humana by 75.7% during the fourth quarter. UMB Bank n.a. now owns 1,304 shares of the insurance provider’s stock worth $334,000 after buying an additional 562 shares during the period. Stifel Financial Corp boosted its stake in Humana by 14.4% in the 4th quarter. Stifel Financial Corp now owns 22,938 shares of the insurance provider’s stock worth $5,875,000 after buying an additional 2,879 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in Humana by 41.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,995 shares of the insurance provider’s stock valued at $517,000 after buying an additional 582 shares during the period. Finally, Bank of Nova Scotia increased its stake in shares of Humana by 366.8% during the 4th quarter. Bank of Nova Scotia now owns 360,793 shares of the insurance provider’s stock valued at $92,410,000 after acquiring an additional 283,505 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.